PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
01-Jul-2025 Senzime Granted New U.S. Patent for TetraGraph System ACCESS Newswire
01-Jul-2025 Alligator to Present 24-Month OPTIMIZE-1 Data at ESMO GI 2025 ACCESS Newswire
01-Jul-2025 Global Newborn Screening Market to witness 6–8% CAGR driven by improved lab capabilities by 2027 MediTech-Insights
01-Jul-2025 Global Diabetes Devices Market to grow at 6% CAGR led by adoption of smart glucose monitors by 2026 MediTech-Insights
01-Jul-2025 Global Nutraceuticals Market growth at 8–9% CAGR fueled by preventive health demand by 2026 MediTech-Insights
01-Jul-2025 Global Ostomy Devices Market expected to grow at 4–5% CAGR driven by aging population by 2026 MediTech-Insights
30-Jun-2025 MedMira Reports Second Quarter Results FY2025 ACCESS Newswire
30-Jun-2025 (UPDATED) Best Creatine For Women Over 40: Creatine Supplement Impact on Menopause ACCESS Newswire
30-Jun-2025 aap Implantate AG closes financial year 2024 successfully - positive developments despite challenging environment aap Implantate AG
30-Jun-2025 Annual Results 2024 bonyf NV
30-Jun-2025 Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity ACCESS Newswire
30-Jun-2025 TRANSPLANT HOPE: NEW TECH TO ASSESS VIABILITY OF DONOR KIDNEYS Accunea
30-Jun-2025 HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy HUTCHMED
30-Jun-2025 OncoZenge: Investor Receives State Administration of Foreign Exchange (SAFE) Approval OncoZenge:
30-Jun-2025 Insights from Exceptional Cancer Survivors: Cure51 Partners with French Bordeaux-based Contract research Organisation Explicyte to proceed with spatial analysis of exceptional Cancer survivors Samples from 40 Countries Cure51
30-Jun-2025 Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Riliprubart
30-Jun-2025 ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP ProQR
30-Jun-2025 Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Stalicla
30-Jun-2025 STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer STORM Therapeutics
30-Jun-2025 Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations Tilray Medical